This Journal of Hematology & Oncology series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.
Submissions should be made through the journal's Editorial Manager system. The deadline for submissions is 31 October 2021.
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target i...
Citation: Journal of Hematology & Oncology 2021 14:161